Abstract
Introduction
Driven by the launch of disease modifying treatments and an expanding patient
population, the Alzheimer' s disease market will more than double over the next
10 years. Late-stage pipeline products such as Pfizer/Medivation' s Dimebon
(latrepirdine) and Johnson & Johnson/Wyeth' s bapineuzumab hold blockbuster
potential. However, the risk of clinical trial failure remains high in this
indication.
Scope of this research
- Forecasts to 2018 for Alzheimer' s disease, total dementia, and mild
cognitive impairment for novel disease-modifying agents in the seven major
markets
- Forecasts to 2018 of current brand reformulations targeting the
symptomatic relief market.
- Provides a global Alzheimer' s disease market snapshot, and analysis of
patient population growth trends in the seven major markets and BRIC nations.
- Discusses the requirement for biomarker development and targeting patients
earlier in the course of their disease.
Research and analysis highlights
With impressive Phase II data, a strong marketing partner, and broad target
population, Datamonitor forecasts multi-billion dollar sales for Pfizer and
Medivation' s Dimebon (latrepirdine) over the forecast period 20092018.
Driven by prescribing in non-ApoE4 allele patients, Datamonitor forecasts
lucrative sales for Johnson & Johnson/Wyeth' s bapineuzumab. Off-label
prescribing for pre-dementia/prodromal Alzheimer' s disease type mild cognitive
impairment patients will add significant revenue towards the end of the
10-year outlook.
It is unlikely that a treatment will be developed which completely halts, or
reverse, the cognitive decline observed in Alzheimer' s disease over the 10
year time horizon. Therefore, a symptomatic market will remain active in this
disease over the forecast period.
Key reasons to purchase this research
- Quantify the current size of the global Alzheimer' s disease market.
- Appreciate the demographic changes leading to anticipated growth in the
Alzheimer' s disease market.
- Quantify the market to 2018 in the US, Japan, and five key European
markets while identifying the major drivers, resistors, and risks.
| 
View Cart
